Type : Constrained
Content : TEXT Mandatory : No Multiple values : No Unique : No |
Description : Essai Clinique dans lequel le patient est inclus<br> |
Possible values :
RT-SU, Other, PAL ANGI 3, SYNFRIZZ, LMS-02, TRUST 62091 EORTC, PAZOGIST, T-DIS-1001, CASSANDRE-1108, APLIPO, ANGIONEXT 0710, LMS-03 (Sarcome 11), DESMOPAZ, ANGIOTAX-PLUS-0906, TOMOREP, FIBROMATOSE WS-RT, DFSP-PAZO, OS II TTP, AcSé Crizotinib, VIT 0910, REGOSARC-1214, CHONDROG, ESTIM LBH, RMS 2005, NRSTS 2005 EPSSG, OS 2006 (Sarcome 9), STRASS 62092 EORTC, Euro-Ewing 99 (Sarcome 1 - EORTC 62981), API-AI (Sarcome 3), 08 SARC 01 (RT-Sarc), SARC-GYN 1, PALSAR II 98 (Sarcome 2), TEPOSSE, ANGI-HE-1110, OUTC'S, GENEWING, SARI, ProActYon, RETROSPECTYON, ISKS , PROFILER, POLY NCR3-TNF GIST, SARCOLIGO, TKI-CPK-1003, IFOS-1, SAKK 56-07, Sarcome 07/0410 (Sarcome 7), Sarcome 04/0205 (Sarcome 4), Sarcome 08/0411 EORTC 62024 (Sarcome 8), EORTC 90061, EORTC 62061, BFR14, SURGIST Sarcome 10/0805 62063 (Sarcome 10), EORTC 62012, EUROSARC ISG-STS 10-01, CREATE EORTC 90101, GOG 0277 / EORTC 55116-62114, ImadGIST, CABONE, CHONRAD, ALDOXORUBICIN-P3-STS-01, EORTC 1202, REGOBONE, HGUS EORTC-62113-55115-STBSG-GCG, CYCLIGIST, EORTC 62005, EORTC 62011, EORTC 62991-22998, EORTC 62022, RAPIRI, BERNIE BO20924, TED12318, CSTI571X2103, NBTXR3, CSTI571X2101-BKM120, NP28021, PeComa, DOVIGIST, AB07001, VE-BASKET, AB11002, E7389-G000-309 ESAI, AB04030, Y-Image, PALETTE VEG110727 62072, VEG105430 GW786034, PO4720, E7389-E044-207 / EORTC 62052, A6181112, A6181004, A6181047, SUCCEED AP 23573-07-32, H3E-EW-S115, CAMN 107 A2103, CAMN 107 A2201, CAMN 107 G2301, CAMN 107 DDE06, CSTI571 JDE74, AMG162 20042006, EPIGIST, EFC 10145, SARC 011 N021157, ET-C-002-07, SABINE, AMG 655 20060324, ET-B-028-06, ET743-OVC-1001, CP13-0707, NP22890, OP690, PICASSO IPM 3001, BAY 73-4506/14874, IPI-926-04, NO21280, NGR-hTNF NGR 016, ET-B008-98 ET743, CSTI571 0203 EORTC 62001-16003 , CRAD001C 2206 , ET743-STS-201 , AB04016, ET743-SAR-1001 , 62043 EORTC, MORAb-004, TH-CR-406 / SARC 021, BP27772, A6181196, BRF 117019 , A4021020, ATRIGE, ZALYPSIS PM104-B-003-10, NBTXR3 301, LDE225, GENSARC, PVNS, VERSATIS faisabilité, NFITOR, NUTLIN 3 - MDM-2 - RO5503781, LEE011 phase I/II liposarcome, LEE011 phase I tumeurs solides, TSAR, CHDM201X2103C, Euro Ewing 2012, PEMBROSARC, SBRT Pédiatrie, ICGC LEIOMYOSARCOMES GSF, BP29428, MARGIC : Evaluation médico-économique, CCGM097X2101, GENMODIF, EQUIMETH2, HEPATOFLUO, MOST (My Own Specific Therapy), SHIVA - Phase II Preuve de concept, MOZOBIL15609 , SALTO-BIO , SALTO-2, SALTO, PACIFIK- GP28153, ABI-007-PST-001 - pédiatrie, KF5503-66, PROSPECTYON, AMG 232, rEECur EORTC 1403: sarcome d'Ewing, GC-BIO-IPC 2013-010, PERMED01-IPC 2014-003, ALTITUDES-1508 , RADIOSARP, PROPAN01, MorphinOgel, GEIS-32 , BLU-285-1101, EZH-202 , PLX108-10, OTMRG, GO28399, ALT GIST, MEME, CRYODESMO, MAPPYACTS, MO29518 BASKET, TRASTS, ET16-047 GIGIST-LB, I5B-MC-JGDJ : ANNOUNCE Ph III, I5B-MC-JGDM , MOTION - méta osseuses - Cryoablation, FIVE PRIME FPA008-002, AcSé-eSMART-CSET, LMS-04, HOPE 207, COMBINAIR3, IMODI, STARTRK-2 (RXDX-101-02), STOP MUCITES , MetZolimOS, ISI-JX, CLDK378A2407 ASCEND10, THEODORA, CABOGIST EORTC 1317 , RNASARC, CRAD001X2109, AVARTHEC, REVENRI, DCC-2618-03-001 INVICTUS, AcSé pembrolizumab, ANITA EORTC1506 , 20140114 DENO, XGEVA AMGEN 20150360, MICCHADO, TAPPAS 105SAR301 TRACON , PROFILER 02, EORTC-1506-STBSG-ANITA, KCP-330-020 SEAL :Selinexor vs Placebo liposarcome, TRAMUNE : ph IB_trabectidine Durvalumab , IsèreADOM, PHRC ETOILE, Sarcome 13 / OS2016, I6F-MC-JJCD, ALCINA, CA209-848, BLU-285-1303 VOYAGER, EORTC 1447-STBSG, EZH-501, NEOSARCOMICS, METRO PD1, RT-Immune, REGOMUNE, ARO-012 CRENOGIST, ETIOSARC, 1443.0001 : phI_BI765063 , DCC-2618-03-002 INTRIGUE, EREMISS: Ph II_regorafenif en maintenance_sarcome, 2102-ONC-102: Ph Ib/II_FT-2102t , COTESARC ML41313, BFR ESS 01: sarcome stromal de l'endomètre, REGISTRI, cirsarc, CONGRATS, E7389-G000-213, 1200.120 : afatinib, PAIRS AJA, CHANCE, ONCOVID-19: SRAS-COV2 , MULTISARC C16-40, REGOSTAT, MEDIPA, SPECTA EORTC 1553, MEGAMOST, 42756493CAN2002 RAGNAR, ONCOVID-21, ADP-0044-002 SPEARHEAD 1, PROTONBIOMARKS: biomarqueurs_ péd et adultes, PASCA: PArcours de Santé au cours du CAncer, LENVAGIST: ph II_lenvatinib + MSS vs MSS_GIST, RAR-IMMUNE, KETACANCER , 208467 IGNYTE ESO, CHIC STS 01, Ce NGEPS-GMFMel ("RIC MEL") , ANRS0001S CoV-POPART , RTSG 2016 UMBRELLA , SUDOPED, PRESOV, REGOMAIN, EORTC 1809STRASS 2, PLANET, AMPHISARC: Ph I/II, OP2C - Observatoire, SACHA: Etude prospective obs_péd, MIRAS, EORTC QLG: sarcome _ QDV, GERICO 14 , ATEZOGIST, GSK 213406, DUNE, AVIATOR2020, FHD-609-C-001, ZN-c3-003, RADIOSARC: MR004 RT _sarcome tissus mous , INBRX109: ph II_ INBRX-109 chondrosarcome, BI 1403-0008, OSII-TTP, MK7902-013, THERAC, PTC596-ONC-008, FaR-RMS, TARSARC : Ph II_ sarcome tissus mous ATR, STEREOSARC, FORTEe : Fort contre le cancer, RAIN-3201 MANTRA, TPN-RAD, IMPRESARC, OSE-279 - C101, ADCT-601-102, TRacKING, PICCandGLUE, GO42286, PH-L19TNFDOX2-03/16 FIBROSARC, TORNADO, NB003-01, BEVANEC, PM1183-C-010-22, DEBOUT-HOSPIT, PH-L19TNFSARC-03/18 FLASH: sarcome tissus mous, IDRX-42-001, PROPHYLOXITIN, SarQuantIRM, CGT9486-21-301(PEAK), AcSé – Vemurafenib , PEMBROCABOSARC, HYPOSARC |